EYP-1901 Approaches a Pivotal Fall

At Retina World Congress, Ashkan M. Abbey, MD, FASRS, FAAO, reviewed the Duravyu clinical development program. Top-line data from the phase 3 LUGANO and LUCIA trials in wet AMD are expected later this year.

By: Ashkan M. Abbey, MD

Retinal Physician May 15, 2026

5 Key Takeaways

1

EYP-1901 is a bioerodible intravitreal insert designed for sustained release of vorolanib in retinal diseases like wet AMD and DME.
2

The phase 3 LUGANO and LUCIA trials for wet AMD are ongoing, with top-line data expected within 3 to 6 months.
3

EYP-1901 has shown potential for long-term visual stability with fewer injections compared to standard anti-VEGF treatments.
4

The program has demonstrated a favorable safety profile, with no serious adverse events reported in previous trials.
5

The phase 2 trials indicated significant reductions in treatment burden and noninferior visual acuity outcomes compared to aflibercept.

Ashkan M. Abbey

Principal Site Investigator, VERONA

Bio: Ashkan M. Abbey, MD, is involved in the VERONA clinical trial program as a principal site investigator. His work discussed in Retinal Physician focuses on diabetic macular edema and the evaluation of sustained-release intravitreal tyrosine kinase inhibitor delivery with vorolanib intravitreal insert therapy. Dr. Abbey has contributed clinical trial perspective on study design, rescue criteria, durability, and safety considerations for emerging retinal therapies in diabetic macular edema.

PentaVision

Retinal Physician

EYP-1901 Approaches a Pivotal Fall

5 Key Takeaways

1

2

3

4

5

Recommendations